Podium to Practice: Chicago 2025 – GU: Gut-associated checkpoint in mRCC
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
4512 – Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.
This program has been made possible through unrestricted support from Ipsen.
Studies/trials discussed:
4512 – Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.